What is VINCERX PHARMA INC's earnings per share (EPS)?

VINCERX PHARMA INC (VINC) reported diluted earnings per share of -$15.85 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

VINCERX PHARMA INC (VINC) Financials

VINC

FY2024 annual

Revenue Not reported for FY2024

Net Income -$30.1M +25.1% YoY

EPS (Diluted) -$15.85 YoY not available

Operating Cash Flow -$26.1M +35.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2025, ended Mar 31, 2025 Reported May 15, 2025 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2025, filed May 15, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VINC SEC filings page.

This page shows VINCERX PHARMA INC (VINC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score not available

VINCERX PHARMA INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

VINCERX PHARMA INC passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

VINCERX PHARMA INC reported a net loss of $30.1M while operations used $26.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$3.3M

YoY+55.3%

VINCERX PHARMA INC's EBITDA was -$3.3M in Q1 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.3% from the same quarter a year earlier.

Net Income

-$5.0M

YoY+59.8%

VINCERX PHARMA INC reported -$5.0M in net income in Q1 2025. This represents an increase of 59.8% from the same quarter a year earlier.

EPS (Diluted)

-$1.40

QoQ+90.8%

VINCERX PHARMA INC earned -$1.40 per diluted share (EPS) in Q1 2025. Against the prior quarter it is up 90.8%.

Revenue

Not reported for Q1 2025.

Cash & Balance Sheet

Cash & Debt

$4.4M

YoY-13.2%

QoQ-11.0%

5Y CAGR+42.7%

VINCERX PHARMA INC held $4.4M in cash as of Q1 2025; long-term debt is not reported for that period.

Shares Outstanding

QoQ0.0%

5Y CAGR-8.6%

VINCERX PHARMA INC had 5M shares outstanding in Q1 2025. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2025.

Dividends Per Share

Not reported for Q1 2025.

Margins & Returns

Return on Equity

-242.0%

VINCERX PHARMA INC's ROE was -242.0% in Q1 2025, measuring profit generated per dollar of shareholder equity.

Gross Margin

Not reported for Q1 2025.

Operating Margin

Not reported for Q1 2025.

Net Margin

Not reported for Q1 2025.

Capital Allocation

R&D Spending

$1.0M

YoY-77.7%

VINCERX PHARMA INC invested $1.0M in research and development in Q1 2025. This represents a decrease of 77.7% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2025.

Capital Expenditures

Not reported for Q1 2025.

VINC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VINC quarterly income statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
R&D Expenses	N/A	$15.5M-46.6%	$29.0M-41.9%	$49.8M+24.3%	$40.1M+1794.2%	$2.1M
SG&A Expenses	N/A	$16.0M+17.2%	$13.6M-27.8%	$18.9M-16.3%	$22.6M+527.4%	$3.6M
Operating Income	N/A	-$31.5M+26.2%	-$42.6M+40.1%	-$71.2M-13.6%	-$62.7M-484.8%	-$10.7M
EBITDA	N/A	-$31.4M+26.2%	-$42.6M+40.2%	-$71.1M-13.6%	-$62.6M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$8K0.0%	$8K
Income Tax	N/A	N/A	N/A	N/A	N/A	$812
Net Income	N/A	-$30.1M+25.1%	-$40.2M+36.2%	-$63.0M-60.2%	-$39.3M-136.5%	-$16.6M
EPS (Basic)	N/A	-$15.85+58.0%	-$37.72-1157.3%	-$3.00-31.0%	-$2.29	N/A
EPS (Diluted)	—	-$15.85	-$37.72	-$3.00-31.0%	-$2.29	N/A
Diluted Shares (Avg)	N/A	1,898	1,065	21,029+22.4%	17,176	N/A

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q
R&D Expenses	$1.0M-77.7%	N/A	$3.9M-35.9%	$3.8M-54.5%	$4.6M-58.2%	N/A	$6.1M-44.9%	$8.2M-40.0%
SG&A Expenses	$2.3M-20.7%	N/A	$3.9M+10.7%	$3.6M-5.2%	$2.9M-35.0%	N/A	$3.5M-22.5%	$3.8M-19.3%
Operating Income	-$3.3M+55.4%	N/A	-$7.8M+18.9%	-$7.4M+38.9%	-$7.5M+51.5%	N/A	-$9.6M+43.1%	-$12.1M+38.5%
EBITDA	-$3.3M+55.3%	N/A	-$7.8M+18.9%	-$7.4M+39.0%	-$7.5M+51.5%	N/A	-$9.6M+43.2%	-$12.0M+38.6%
Net Income	-$5.0M+59.8%	N/A	-$7.8M+12.9%	-$1.8M+84.3%	-$12.4M+15.2%	N/A	-$9.0M+46.6%	-$11.6M+37.3%
EPS (Basic)	-$1.40+87.8%	-$15.22+57.8%	-$0.17+59.5%	-$0.05+90.7%	-$11.46-1560.9%	-$36.06-6577.8%	-$0.42+47.5%	-$0.54+38.6%
EPS (Diluted)	-$1.40	-$15.22	-$15.85	-$0.05	-$11.46	-$36.06-6577.8%	-$37.72	-$0.54+38.6%
Diluted Shares (Avg)	3,580	N/A	45,672	38,339	1,085	N/A	21,345	21,274+1.3%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

VINC Balance Sheet

VINC quarterly balance sheet

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$8.0M-56.1%	$18.2M-69.3%	$59.3M-49.6%	$117.7M+86.2%	$63.2M
Current Assets	$6.4M-56.5%	$14.7M-73.7%	$56.0M-50.0%	$111.8M+77.2%	$63.1M
Cash & Equivalents	$5.0M-61.0%	$12.8M+9.6%	$11.7M-89.5%	$111.5M+80.4%	$61.8M
Short-Term Investments	$0	$0-100.0%	$40.8M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0
Total Liabilities	$5.3M-24.5%	$7.0M-39.8%	$11.6M-33.1%	$17.4M-54.1%	$37.8M
Current Liabilities	$5.3M-5.8%	$5.6M-38.8%	$9.2M-34.2%	$13.9M-63.2%	$37.8M
Non-Current Liabilities	$0-100.0%	$1.4M-43.5%	$2.5M-28.3%	$3.4M	$0
Total Equity	$2.7M-75.7%	$11.2M-76.5%	$47.7M-52.5%	$100.3M+295.3%	$25.4M
Retained Earnings	-$189.2M-18.9%	-$159.1M-33.8%	-$119.0M-112.5%	-$56.0M-235.9%	-$16.7M

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q
Total Assets	$4.7M-57.7%	$8.0M-56.1%	$14.9M-43.1%	$21.5M-39.0%	$11.1M-76.6%	$18.2M-69.3%	$26.3M-63.7%	$35.3M-59.8%
Current Assets	$4.7M-39.0%	$6.4M-56.5%	$11.7M-48.5%	$18.3M-42.5%	$7.7M-82.6%	$14.7M-73.7%	$22.8M-66.1%	$31.8M-61.4%
Cash & Equivalents	$4.4M-13.2%	$5.0M-61.0%	$2.9M-80.5%	$7.9M+18.6%	$5.1M+13.8%	$12.8M+9.6%	$15.1M-67.1%	$6.7M-91.7%
Short-Term Investments	$0	$0	$7.1M+24.8%	$8.4M-59.4%	$0-100.0%	$0-100.0%	$5.7M-71.6%	$20.7M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.6M-77.6%	$5.3M-24.5%	$5.8M-44.6%	$6.1M-45.4%	$11.7M-9.8%	$7.0M-39.8%	$10.5M-16.8%	$11.1M-16.8%
Current Liabilities	$2.6M-75.4%	$5.3M-5.8%	$5.4M-38.7%	$5.3M-41.8%	$10.6M-0.7%	$5.6M-38.8%	$8.8M-11.1%	$9.2M-12.4%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$415K-75.4%	$747K-62.3%	$1.1M-52.8%	$1.4M-43.5%	$1.7M-37.9%	$2.0M-32.4%
Total Equity	$2.1M+432.2%	$2.7M-75.7%	$9.1M-42.1%	$15.4M-36.0%	-$622K-101.8%	$11.2M-76.5%	$15.7M-73.6%	$24.1M-67.5%
Retained Earnings	-$194.2M-13.2%	-$189.2M-18.9%	-$181.2M-15.7%	-$173.3M-18.1%	-$171.5M-26.4%	-$159.1M-33.8%	-$156.5M-45.4%	-$146.8M-61.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

VINC Cash Flow Statement

VINC quarterly cash flow statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$22.8M	-$26.1M+35.4%	-$40.5M+32.1%	-$59.6M-78.4%	-$33.4M-1365.6%	-$2.3M
Depreciation & Amortization	N/A	$52K0.0%	$52K-3.7%	$54K+116.0%	$25K	N/A
Stock-Based Compensation	N/A	$3.5M-2.5%	$3.6M-64.6%	$10.1M-56.9%	$23.3M+432.0%	$4.4M
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$258K	N/A
Free Cash Flow	N/A	N/A	N/A	-$59.6M-77.1%	-$33.7M	N/A
Investing Cash Flow	N/A	$212K-99.5%	$41.5M+202.3%	-$40.6M-671.7%	-$5.3M+92.0%	-$65.6M
Financing Cash Flow	$21.8M	$18.0M+15682.5%	$114K-59.3%	$280K-99.7%	$88.5M+38.1%	$64.1M

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q
Operating Cash Flow	-$4.5M+42.4%	-$6.2M+22.9%	-$6.4M+4.0%	-$5.8M+54.1%	-$7.7M+40.9%	-$8.0M+42.0%	-$6.6M+55.3%	-$12.7M+20.1%
Depreciation & Amortization	$0-100.0%	$13K+8.3%	$13K-7.1%	$13K0.0%	$13K0.0%	$12K-14.3%	$14K+7.7%	$13K0.0%
Stock-Based Compensation	$435K-17.6%	N/A	$1.4M+126.2%	$912K-16.6%	$528K-61.8%	N/A	$629K-72.5%	$1.1M-67.5%
Investing Cash Flow	N/A	$7.2M+24.8%	$1.4M-90.9%	-$8.3M-156.3%	$0-100.0%	$5.8M+128.2%	$15.1M+174.6%	$14.8M
Financing Cash Flow	$3.9M+77020.0%	$985K+5372.2%	$0	$17.0M+18181.7%	$5K+66.7%	$18K-52.6%	$0	$93K-61.6%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

VINC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VINC quarterly financial ratios

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Return on Equity	-1104.0%-746.2pp	-357.8%-225.7pp	-132.1%-93.0pp	-39.2%+26.3pp	-65.5%
Return on Assets	-375.7%-155.2pp	-220.4%-114.2pp	-106.2%-72.8pp	-33.4%-7.1pp	-26.3%
Current Ratio	1.21-1.4x	2.63-3.5x	6.11-1.9x	8.04+6.4x	1.67
Debt-to-Equity	1.94+1.3x	0.62+0.4x	0.24+0.1x	0.17-1.3x	1.49

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q
Return on Equity	-242.0%	N/A	-86.1%-28.9pp	-11.7%+36.1pp	N/A	N/A	-57.2%-29.0pp	-47.9%-23.1pp
Return on Assets	-106.7%+5.4pp	N/A	-52.5%-18.2pp	-8.4%+24.3pp	-112.1%-81.3pp	N/A	-34.3%-11.0pp	-32.7%-11.8pp
Current Ratio	1.79+1.1x	1.21-1.4x	2.17-0.4x	3.430.0x	0.72-3.4x	2.63-3.5x	2.58-4.2x	3.47-4.4x
Debt-to-Equity	1.27	1.94+1.3x	0.640.0x	0.39-0.1x	N/A	0.62+0.4x	0.67+0.5x	0.46+0.3x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
VINCERX PHARMA INC VINC	FY2024	N/A	-$30.1M	N/A	N/A	—
TREVENA INC TRVN	FY2023	N/A	-$40.3M	N/A	$1.3M	—
SCORPIUS HOLDINGS INC SCPX	FY2024	$6.2M	-$32.8M	N/A	$1.5M	—

Where VINCERX PHARMA INC Ranks

Frequently Asked Questions

Is VINCERX PHARMA INC profitable?

No, VINCERX PHARMA INC (VINC) reported a net income of -$30.1M in fiscal year 2024.

What is VINCERX PHARMA INC's EBITDA?

VINCERX PHARMA INC (VINC) had EBITDA of -$31.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is VINCERX PHARMA INC's return on equity (ROE)?

VINCERX PHARMA INC (VINC) has a return on equity of -1104.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is VINCERX PHARMA INC's operating cash flow?

VINCERX PHARMA INC (VINC) recorded an outflow of $26.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

What are VINCERX PHARMA INC's total assets?

VINCERX PHARMA INC (VINC) had $8.0M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does VINCERX PHARMA INC spend on research and development?

VINCERX PHARMA INC (VINC) invested $15.5M in research and development during fiscal year 2024.

How many shares does VINCERX PHARMA INC have outstanding?

VINCERX PHARMA INC (VINC) had 5M shares outstanding as of fiscal year 2024.

What is VINCERX PHARMA INC's current ratio?

VINCERX PHARMA INC (VINC) had a current ratio of 1.21 as of fiscal year 2024, which is considered adequate.

What is VINCERX PHARMA INC's debt-to-equity ratio?

VINCERX PHARMA INC (VINC) had a debt-to-equity ratio of 1.94 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is VINCERX PHARMA INC's return on assets (ROA)?

VINCERX PHARMA INC (VINC) had a return on assets of -375.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

How does VINCERX PHARMA INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2024, VINCERX PHARMA INC (VINC) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.1M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is VINCERX PHARMA INC's Piotroski F-Score?

VINCERX PHARMA INC (VINC) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are VINCERX PHARMA INC's earnings high quality?

VINCERX PHARMA INC (VINC) reported a net loss of $30.1M while operations used $26.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.